文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

载脂蛋白 L5 和 Lp(a)在动脉粥样硬化性心血管疾病中的对比分析。

Comparative Analysis of Atherogenic Lipoproteins L5 and Lp(a) in Atherosclerotic Cardiovascular Disease.

机构信息

Molecular Cardiology Research Laboratories, Vascular and Medicinal Research, The Texas Heart Institute, Houston, Texas, 77030, USA.

Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, Texas, 77030, USA.

出版信息

Curr Atheroscler Rep. 2024 Jul;26(7):317-329. doi: 10.1007/s11883-024-01209-3. Epub 2024 May 16.


DOI:10.1007/s11883-024-01209-3
PMID:38753254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11192678/
Abstract

PURPOSE OF REVIEW: Low-density lipoprotein (LDL) poses a risk for atherosclerotic cardiovascular disease (ASCVD). As LDL comprises various subtypes differing in charge, density, and size, understanding their specific impact on ASCVD is crucial. Two highly atherogenic LDL subtypes-electronegative LDL (L5) and Lp(a)-induce vascular cell apoptosis and atherosclerotic changes independent of plasma cholesterol levels, and their mechanisms warrant further investigation. Here, we have compared the roles of L5 and Lp(a) in the development of ASCVD. RECENT FINDINGS: Lp(a) tends to accumulate in artery walls, promoting plaque formation and potentially triggering atherosclerosis progression through prothrombotic or antifibrinolytic effects. High Lp(a) levels correlate with calcific aortic stenosis and atherothrombosis risk. L5 can induce endothelial cell apoptosis and increase vascular permeability, inflammation, and atherogenesis, playing a key role in initiating atherosclerosis. Elevated L5 levels in certain high-risk populations may serve as a distinctive predictor of ASCVD. L5 and Lp(a) are both atherogenic lipoproteins contributing to ASCVD through distinct mechanisms. Lp(a) has garnered attention, but equal consideration should be given to L5.

摘要

目的综述:低密度脂蛋白(LDL)可导致动脉粥样硬化性心血管疾病(ASCVD)。由于 LDL 包含在电荷、密度和大小上有所不同的各种亚型,因此了解它们对 ASCVD 的具体影响至关重要。两种高度致动脉粥样硬化的 LDL 亚型——负电性 LDL(L5)和 Lp(a)——独立于血浆胆固醇水平诱导血管细胞凋亡和动脉粥样硬化变化,其机制值得进一步研究。在这里,我们比较了 L5 和 Lp(a) 在 ASCVD 发展中的作用。

最近的发现:Lp(a) 倾向于在动脉壁中积累,通过促血栓形成或抗纤维蛋白溶解作用促进斑块形成并可能引发动脉粥样硬化进展。高 Lp(a) 水平与钙化性主动脉狭窄和动脉粥样硬化血栓形成风险相关。L5 可诱导内皮细胞凋亡,增加血管通透性、炎症和动脉粥样硬化形成,在引发动脉粥样硬化中起关键作用。某些高危人群中升高的 L5 水平可能是 ASCVD 的一个独特预测因子。L5 和 Lp(a) 都是致动脉粥样硬化的脂蛋白,通过不同的机制导致 ASCVD。Lp(a) 引起了关注,但同样应考虑 L5。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8f/11192678/07e199654c88/11883_2024_1209_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8f/11192678/a2ac57410184/11883_2024_1209_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8f/11192678/07e199654c88/11883_2024_1209_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8f/11192678/a2ac57410184/11883_2024_1209_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8f/11192678/07e199654c88/11883_2024_1209_Fig2_HTML.jpg

相似文献

[1]
Comparative Analysis of Atherogenic Lipoproteins L5 and Lp(a) in Atherosclerotic Cardiovascular Disease.

Curr Atheroscler Rep. 2024-7

[2]
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.

Cardiovasc Drugs Ther. 2019-12

[3]
Lipoprotein(a) is a highly atherogenic lipoprotein: pathophysiological basis and clinical implications.

Curr Opin Cardiol. 2024-11-1

[4]
Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis.

Circ Res. 2009-3-13

[5]
Electronegative LDL: An Active Player in Atherogenesis or a By- Product of Atherosclerosis?

Curr Med Chem. 2019

[6]
Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies.

Clin Res Cardiol Suppl. 2017-3

[7]
Autoimmune Rheumatic Diseases: An Update on the Role of Atherogenic Electronegative LDL and Potential Therapeutic Strategies.

J Clin Med. 2021-5-6

[8]
[Front line of oxidized lipoproteins: role of oxidized lipoproteins in atherogenesis and cardiovascular disease risk].

Rinsho Byori. 2010-6

[9]
Lipoprotein(a) accelerates atherosclerosis in uremic mice.

J Lipid Res. 2010-6-28

[10]
Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesioned rabbit aorta.

J Clin Invest. 1996-7-15

引用本文的文献

[1]
Prevalence, Clinical Characteristics and Prognosis of Vascular Disease in Valvular Heart Surgery: A Multi-Centre Study.

Glob Heart. 2025-8-28

[2]
Gene Therapy Approaches for Atherosclerosis Focusing on Targeting Lipid Metabolism and Inflammation.

Int J Mol Sci. 2025-7-19

[3]
Atherogenic circulating lipoproteins in ischemic stroke.

Front Cardiovasc Med. 2024-12-6

本文引用的文献

[1]
Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease.

J Am Coll Cardiol. 2024-3-5

[2]
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome.

Can J Cardiol. 2023-10

[3]
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.

N Engl J Med. 2022-11-17

[4]
There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.

Am J Prev Cardiol. 2022-8-6

[5]
Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology.

Atherosclerosis. 2022-5

[6]
Small dense low-density lipoprotein particles: clinically relevant?

Curr Opin Lipidol. 2022-6-1

[7]
Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease.

J Pers Med. 2022-2-12

[8]
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.

Arterioscler Thromb Vasc Biol. 2022-1

[9]
Innate immune detection of lipid oxidation as a threat assessment strategy.

Nat Rev Immunol. 2022-5

[10]
Lipoprotein (a) level as a risk factor for stroke and its subtype: A systematic review and meta-analysis.

Sci Rep. 2021-8-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索